IPSWICH, Mass., Nov. 8, 2021 /PRNewswire/ -- New England
Biolabs (NEB®) announced today that they have released a kit for
the generation of in vitro transcribed synthetic mRNA capped
using the TriLink Biotechnologies, part of Maravai LifeSciences
(NASDAQ: MRVI), CleanCap Reagent AG.
NEB's portfolio of HiScribe in
vitro transcription (IVT) kits is designed to simplify
workflows while producing high yields of
RNA. The new HiScribe T7 mRNA Kit with CleanCap
Reagent AG produces a high yield of mRNA with a Cap
1 structure in a single-step reaction for research
and preclinical workflows. Messenger RNAs with Cap 1
structures are desirable
for increased biological activity and reduced
immunogenicity. When manufacturing scales increase,
NEB's in vitro transcription kits,
reagents and enzymes can be obtained in large
quantities, including GMP-grade* quality, allowing a
seamless transition to large-scale therapeutic mRNA manufacturing,
including vaccine production.
"Over the past year and a half, the use of synthetic mRNA
vaccines has proven the effectiveness of mRNA as a therapeutic
modality," stated Ted Davis,
Executive Director of Business and Product Development at
NEB. "The new HiScribe T7 mRNA Kit
with CleanCap Reagent AG combines NEB's deep
expertise in enzymology
with TriLink's novel CleanCap technology,
enabling the acceleration of research and development
by allowing scientists to easily generate
high-quality mRNA and quickly screen many different molecules or
designs."
"TriLink is proud to be included in the next generation of NEB
in vitro transcription kits," said Brian Neel, Chief Operating Officer of TriLink
Biotechnologies. "The inclusion of our CleanCap Reagent AG is a
momentous step in the dissemination of CleanCap, making it even
easier than before for scientists to generate superior performing
mRNA, with a Cap 1 structure, in a single-pot reaction. The
HiScribe platform is a perfect complement to CleanCap
technology."
TriLink's San Diego CA
headquarters has grown to enable TriLink to meet the global demand
for CleanCap reagent and supports several COVID-19 vaccine programs
globally. TriLink also recently expanded manufacturing capabilities
for nucleoside triphosphates, as well as for their contract
development and manufacturing organization services, which now
include plasmid DNA manufacturing for mRNA-based therapeutics and
vaccine production.
More information on the HiScribe T7 mRNA Kit with CleanCap
Reagent AG can be found at www.neb.com/E2080.
More information on NEB's portfolio of GMP-grade IVT reagents
can be found at www.neb.com/GMP
More information on TriLink's CleanCap Reagent can be found at
https://www.trilinkbiotech.com/cleancap/
*"GMP-grade" is a branding term NEB uses to describe reagents
manufactured at our Rowley, MA
facility, where we utilize procedures and process controls to
manufacture reagents under more rigorous conditions to
achieve more stringent product specifications, and in
compliance with ISO 9001 and ISO 13485 quality management system
standards. NEB does not manufacture or sell products known as
Active Pharmaceutical Ingredients (APIs), nor do we manufacture
products in compliance with all the Current Good Manufacturing
Practice regulations.
About New England Biolabs
Established in the mid
1970s, New England Biolabs, Inc. is the industry leader in the
discovery and production of enzymes for molecular biology
applications and now offers the largest selection of recombinant
and native enzymes for genomic research. NEB continues to expand
its product offerings into areas related to PCR, gene expression,
sample preparation for next generation sequencing, synthetic
biology, glycobiology, epigenetics and RNA analysis.
Additionally, NEB is focused on strengthening alliances that enable
new technologies to reach key market sectors, including the
development of molecular diagnostics, as well as nucleic
acid vaccines. New England Biolabs is a privately held
company, headquartered in Ipswich,
MA, USA, and has extensive worldwide distribution through
a network of exclusive distributors, agents
and eight subsidiaries located in Australia, Canada, China, France, Germany, Japan, Singapore, and the UK. For more
information about New England Biolabs visit www.neb.com.
NEW ENGLAND BIOLABS® and
NEB® are registered trademarks of New England
Biolabs, Inc.
About TriLink Biotechnologies
TriLink Biotechnologies, part of Maravai LifeSciences (NASDAQ:
MRVI), is a CDMO helping life science leaders and innovators
overcome challenges in the synthesis and scale-up of nucleic acids,
NTPs, and mRNA capping analogs with scale-up expertise and unique
mRNA production capabilities, including its proprietary
CleanCap® mRNA capping
technology. TriLink continues to expand its cGMP and
general manufacturing capacity at its new global headquarters in
San Diego, California, to support
mRNA, oligonucleotide, and plasmid production for therapeutic,
vaccine, and diagnostic
customers. www.trilinkbiotech.com
CLEANCAP® and TRILINK® are registered trademarks of TriLink
Biotechnologies, LLC.
About Maravai LifeSciences
Maravai is a leading
life sciences company providing critical products to enable the
development of drug therapies, diagnostics, novel vaccines, and
support research on human diseases. Maravai's companies are leaders
in providing products and services in the fields of nucleic acid
synthesis and biologic safety testing to many of the world's
leading biopharmaceutical, vaccine, diagnostics, and cell and gene
therapy companies.
For more information about Maravai LifeSciences, visit
www.maravai.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/new-england-biolabs-releases-next-generation-hiscribe-in-vitro-transcription-kit-incorporating-trilink-biotechnologies-cleancap-technology-for-mrna-synthesis-301418815.html
SOURCE New England Biolabs